A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity

Exclusion Criteria

• •Weight loss \>2% in the previous 3 months for patients ≥18 years of age or \>2% reduction in BMI for patients \<18 years of age
• •History of major surgical procedure within 30 days
• •HbA1c \>10.9%
• •Fasting glucose level \>270 mg/dL
• •Previous use of MC4R agonists
• •Diagnosis of Prader-Willi syndrome (PWS) or Rapid-onset obesity with hypoventilation, hypothalamic, autonomic dysregulation, neuroendocrine tumor syndrome (ROHHADNET).
• •Diagnosis of severe psychiatric disorders; any suicidal ideation, attempt or behavior
• •History or close family history of skin cancer or melanoma
• •Current clinically significant pulmonary, cardiac, or oncologic disease considered severe enough to interfere with the study and/or confound the results